Literature DB >> 20237971

A comparison of venlafaxine and SSRIs in deliberate self-poisoning.

Agnes N Chan1, Naren Gunja, Christopher J Ryan.   

Abstract

To compare the clinical features of deliberate self-poisoning with venlafaxine and selective serotonin reuptake inhibitors (SSRIs) presenting to the emergency department of an Australian tertiary referral hospital. A retrospective cohort study comparing all 36 patients who presented with venlafaxine self-poisoning with 44 randomly selected patients with SSRI self-poisoning between 1997 and 2006. Patients who had overdosed on venlafaxine were older (mean age 37.4 versus 28.8 years, p ≤ 0.001) and generally exhibited a higher degree of suicidal intent (p ≤ 0.017). Median venlafaxine dose taken was 35 defined daily doses (DDDs) compared with SSRIs 19.4 DDDs. Those who ingested venlafaxine were more likely to become confused (25% versus 0%; p = 0) and have mydriasis (19.4% versus 2%; p ≤ 0.02), than those who took SSRIs. One patient from the venlafaxine group died. Compared with SSRI self-poisoners, patients who deliberately ingested venlafaxine were more likely to exhibit serious suicide intent. They were also more likely to be older, take a higher DDD of the drug, and have confusion and mydriasis. This has implications for management of severely depressed and suicidal patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237971      PMCID: PMC3550301          DOI: 10.1007/s13181-010-0013-x

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  18 in total

1.  Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000.

Authors:  Survjit Cheeta; Fabrizio Schifano; Adenekan Oyefeso; Lucy Webb; A Hamid Ghodse
Journal:  Br J Psychiatry       Date:  2004-01       Impact factor: 9.319

2.  The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity.

Authors:  E J C Dunkley; G K Isbister; D Sibbritt; A H Dawson; I M Whyte
Journal:  QJM       Date:  2003-09

3.  Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose.

Authors:  Geoffrey K Isbister; Lena E Friberg; Stephen B Duffull
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

4.  Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes.

Authors:  M Khalifa; P Daleau; a J Turgeon
Journal:  J Pharmacol Exp Ther       Date:  1999-10       Impact factor: 4.030

Review 5.  The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database.

Authors:  R L Rudolph; A T Derivan
Journal:  J Clin Psychopharmacol       Date:  1996-06       Impact factor: 3.153

6.  Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data.

Authors:  Anna Koski; Erkki Vuori; Ilkka Ojanperä
Journal:  Int J Legal Med       Date:  2005-03-01       Impact factor: 2.686

7.  Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants.

Authors:  I M Whyte; A H Dawson; N A Buckley
Journal:  QJM       Date:  2003-05

8.  Fatal toxicity of antidepressants in England and Wales, 1993-2002.

Authors:  Oliver Morgan; Clare Griffiths; Allan Baker; Azeem Majeed
Journal:  Health Stat Q       Date:  2004

9.  Venlafaxine (Effexor): concerns about increased risk of fatal outcomes in overdose.

Authors:  Dorian Deshauer
Journal:  CMAJ       Date:  2006-12-13       Impact factor: 8.262

10.  Comparative toxicity of citalopram and the newer antidepressants after overdose.

Authors:  C A Kelly; N Dhaun; W J Laing; F E Strachan; A M Good; D N Bateman
Journal:  J Toxicol Clin Toxicol       Date:  2004
View more
  3 in total

Review 1.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

2.  A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose.

Authors:  David Taylor; Alan Lenox-Smith; Andrew Bradley
Journal:  Ther Adv Psychopharmacol       Date:  2013-06

3.  Cases of adverse reaction to psychotropic drugs and possible association with pharmacogenetics.

Authors:  Irina Piatkov; Trudi Jones; Mark McLean
Journal:  J Pers Med       Date:  2012-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.